Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

561 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
Sborov DW, Baljevic M, Reeves B, Laubach J, Efebera YA, Rodriguez C, Costa LJ, Chari A, Silbermann R, Holstein SA, Anderson LD Jr, Kaufman JL, Shah N, Pei H, Patel S, Cortoos A, Bartlett JB, Vermeulen J, Lin TS, Voorhees PM, Richardson PG. Sborov DW, et al. Among authors: richardson pg. Br J Haematol. 2022 Nov;199(3):355-365. doi: 10.1111/bjh.18432. Epub 2022 Sep 16. Br J Haematol. 2022. PMID: 36111391 Free PMC article. Clinical Trial.
Management of relapsed multiple myeloma after autologous stem cell transplant.
Holstein SA, Richardson PG, Laubach JP, McCarthy PL. Holstein SA, et al. Among authors: richardson pg. Biol Blood Marrow Transplant. 2015 May;21(5):793-8. doi: 10.1016/j.bbmt.2014.12.026. Epub 2015 Jan 31. Biol Blood Marrow Transplant. 2015. PMID: 25652690 Free article. Review.
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orlowski RZ, Moreau P, Rosiñol L, Faber EA Jr, Voorhees P, Mateos MV, Marquez L, Feng H, Desai A, van de Velde H, Elliott J, Shi H, Dow E, Jobanputra N, Esseltine DL, Niculescu L, Anderson KC, Lonial S, Richardson PG. Laubach JP, et al. Among authors: richardson pg. Br J Haematol. 2017 Aug;178(4):547-560. doi: 10.1111/bjh.14708. Epub 2017 May 3. Br J Haematol. 2017. PMID: 28466536 Free PMC article.
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.
Richardson PG, Bensinger WI, Huff CA, Costello CL, Lendvai N, Berdeja JG, Anderson LD Jr, Siegel DS, Lebovic D, Jagannath S, Laubach JP, Stockerl-Goldstein KE, Kwei L, Clow F, Elias L, Salman Z, Graef T, Bilotti E, Vij R. Richardson PG, et al. Br J Haematol. 2018 Mar;180(6):821-830. doi: 10.1111/bjh.15058. Epub 2018 Feb 13. Br J Haematol. 2018. PMID: 29435979 Free PMC article. Clinical Trial.
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.
O'Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, Basile FG, Wade PM, Paba-Prada CE, Ghobrial IM, Schlossman RL, Burke JN, Harrington CC, Lively KJ, Lyons HF, Munshi NC, Anderson KC, Trippa L, Richardson PG, Raje NS. O'Donnell EK, et al. Among authors: richardson pg. Br J Haematol. 2018 Jul;182(2):222-230. doi: 10.1111/bjh.15261. Epub 2018 May 8. Br J Haematol. 2018. PMID: 29740809 Free PMC article. Clinical Trial.
Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1.
Bringhen S, Voorhees PM, Plesner T, Mellqvist UH, Reeves B, Sonneveld P, Byrne C, Nordström E, Harmenberg J, Obermüller J, Richardson PG. Bringhen S, et al. Among authors: richardson pg. Br J Haematol. 2021 Jun;193(6):1105-1109. doi: 10.1111/bjh.17302. Epub 2021 Jan 6. Br J Haematol. 2021. PMID: 33403663 Free PMC article. Clinical Trial.
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).
Voorhees PM, Suman VJ, Tuchman SA, Laubach JP, Hassoun H, Efebera YA, Mulkey F, Bova-Solem M, Santo K, Carlisle D, McCarthy PL, Richardson PG. Voorhees PM, et al. Among authors: richardson pg. Am J Hematol. 2021 Dec 1;96(12):1595-1603. doi: 10.1002/ajh.26361. Epub 2021 Oct 6. Am J Hematol. 2021. PMID: 34559902 Free PMC article. Clinical Trial.
Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN.
Nooka AK, Kaufman JL, Rodriguez C, Jakubowiak A, Efebera Y, Reeves B, Wildes T, Holstein SA, Anderson LD Jr, Badros A, Shune L, Chari A, Pei H, Cortoos A, Patel S, Bartlett JB, Vermeulen J, Lin TS, Richardson PG, Voorhees P. Nooka AK, et al. Among authors: richardson pg. Blood Cancer J. 2022 Apr 13;12(4):63. doi: 10.1038/s41408-022-00653-1. Blood Cancer J. 2022. PMID: 35418120 Free PMC article. No abstract available.
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Murphy S, Lutska Y, Pei H, Ukropec J, Vermeulen J, de Boer C, Hoehn D, Lin TS, Richardson PG. Voorhees PM, et al. Among authors: richardson pg. Blood. 2020 Aug 20;136(8):936-945. doi: 10.1182/blood.2020005288. Blood. 2020. PMID: 32325490 Free PMC article. Clinical Trial.
561 results